Patents by Inventor MATTHEW LOUIS HIRSCH

MATTHEW LOUIS HIRSCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vector-mediated immune tolerance in the eye
    Patent number: 11866480
    Abstract: This invention relates to vectors for delivery of human leukocyte antigen G to the eye and/or to cornea explants and methods of using the same for treatment and/or prevention of corneal transplant rejection and other disorders associated with an immune response and/or vascularization.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: January 9, 2024
    Assignees: The University of North Carolina at Chapel Hill, North Carolina State University
    Inventors: Matthew Louis Hirsch, Brian Christopher Gilger
  • AAV-IDUA VECTOR FOR TREATMENT OF MPS I-ASSOCIATED BLINDNESS
    Publication number: 20220047721
    Abstract: This invention relates to viral vectors for delivery of alpha-L-iduronidase to the cornea of a subject and methods of using the same for treatment and prevention of corneal clouding and blindness in a subject due to mucopolysaccharidosis I.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 17, 2022
    Inventors: Matthew Louis Hirsch, Richard Jude Samulski
  • VECTOR-MEDIATED IMMUNE TOLERANCE IN THE EYE
    Publication number: 20210292388
    Abstract: This invention relates to vectors for delivery of human leukocyte antigen G to the eye and/or to cornea explants and methods of using the same for treatment and/or prevention of corneal transplant rejection and other disorders associated with an immune response and/or vascularization.
    Type: Application
    Filed: July 26, 2017
    Publication date: September 23, 2021
    Inventors: Matthew Louis Hirsch, Brian Christopher Gilger
  • AAV-IDUA vector for treatment of MPS I-associated blindness
    Patent number: 11116850
    Abstract: This invention relates to viral vectors for delivery of alpha-L-iduronidase to the cornea of a subject and methods of using the same for treatment and prevention of corneal clouding and blindness in a subject due to mucopolysaccharidosis I.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: September 14, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Matthew Louis Hirsch, Richard Jude Samulski
  • TRUNCATED DYSFERLIN FOR TREATMENT OF DYSFERLINOPATHY
    Publication number: 20200010521
    Abstract: This invention relates to a truncated dysferlin nucleic acid and protein, vectors (e.g., adeno-associated virus vectors) comprising the nucleic acid and methods of using the same for delivery of dysferlin to a cell or a subject and treating dysferlinopathy.
    Type: Application
    Filed: June 16, 2017
    Publication date: January 9, 2020
    Inventors: Matthew Louis Hirsch, R. Bryan Sutton
  • AAV-IDUA Vector for Treatment of MPS I-Associated Blindness
    Publication number: 20190048363
    Abstract: This invention relates to viral vectors for delivery of alpha-L-iduronidase to the cornea of a subject and methods of using the same for treatment and prevention of corneal clouding and blindness in a subject due to mucopolysaccharidosis I.
    Type: Application
    Filed: February 22, 2017
    Publication date: February 14, 2019
    Inventors: Matthew Louis Hirsch, Richard Jude Samulski
  • Synthetic adeno-associated virus inverted terminal repeats
    Patent number: 9447433
    Abstract: This invention relates to synthetic adeno-associated virus (AAV) inverted terminal repeats (ITRs) that exhibit altered activities compared to a naturally occurring AAV ITR and methods of using the same for delivery of nucleic acids to a cell or a subject. The synthetic ITRs provide a larger packaging capacity and the ability to manipulate activities such as transduction efficiency, cellular response to transduction, and transcription.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Matthew Louis Hirsch, Richard Jude Samulski
  • Synthetic Adeno-Associated Virus Inverted Terminal Repeats
    Publication number: 20140271551
    Abstract: This invention relates to synthetic adeno-associated virus (AAV) inverted terminal repeats (ITRs) that exhibit altered activities compared to a naturally occurring AAV ITR and methods of using the same for delivery of nucleic acids to a cell or a subject. The synthetic ITRs provide a larger packaging capacity and the ability to manipulate activities such as transduction efficiency, cellular response to transduction, and transcription.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: MATTHEW LOUIS HIRSCH, RICHARD JUDE SAMULSKI